For cutaneous melanoma, BRAF mutation has been a point of interest for potential targeted therapy in metastatic melanoma; however, there are only a few publications consisting of single reports regarding BRAF with or without MEK inhibition in CM. This evidence concerns the gene BRAF and cutaneous melanoma.